Obesity Cagrisema drugs will be an important product

Copenhagen, Denmark – Novo nordisk Protecting the disappointing test results for his heavily dissolved drug candidate next generation Cagrisema, insisting that it will be “important” treatment of weight loss.

On Thursday, CEO Lars Freergard Jorgensen acknowledged a sharp reaction of the share prices after two consecutive tests at the late stage, which showed weight loss compared to the company’s own goals, but stated that he still “remained” encouraged “the profile of weight loss.

“I am very confident in Cagrisema,” he said at the annual general meeting of the company in Copenhagen, Denmark.

“It will be an important product for us.”

Cagrisema is a combination of Cagrilintide – a charged form of weight loss treatment, known as an analogue of amilin – and semaglutide, active substance in the veg.

The headline follows as a result of a joint process liberated Earlier this month, Cagrisema assisted adult patients with overweight with type 2 diabetes will lose 15.7% of their weight within 68 weeks compared to 3.1% of placebo. It was below a high percentage of weighing loss before.

A preliminary test at the late stage publish In December, they showed that the drug helped patients with obesity or overweight with one or more converse diseases, but not type 2 diabetes, reducing their weight by 22.7% after 68 weeks, also below 25%.

Both results destroyed considerable value from NOVO’s stock, as investors hope to find a greater alternative to the existing company wegovy and competitor Eli Lily ZEPBOUND, Both GLP-1 medicines were spoiled. Once upon a time, your favorite shares have now decreased by more than 50% compared to the 2024 highs.

The Danish pharmaceutical giant again collided with the shutdown on Thursday, when the shareholders called on the council to more clear and tactically reasonable trials and goals, trying to provoke less dramatic prices for stocks.

Fruergaard Jørgensen has recognized criticism, especially around the firm’s inability to convey a flexible trial design that caused tolerance questions, with less than two third patients who went to the highest dose after 68 weeks.

“22.7% are not 25%, so some people were disappointed,” he said, but adding that the firm believes there is a “constant potential for further development of Cagrisema”, including by expanding the test period and a total dosage.

Currently, Novo Nordisk pursues a new test 3 phase, called Revefine 11, which “will further” study the potential of Cagrisema “, said the CEO.

This occurs when the weight loss industry remains divided into broader use and the results of obesity drugs that exceed the overall weight loss. In the note earlier this month, Bofa Global Research stated that it became “a little more careful on differentiation” with obesity and treatment of diabetes after the latest Cagrisema results.

However Soren Lontoft, Pharma Equity Analyst at Sydbank, detach Last week, CNBC is the need for a variety of treatment complex to solve both the obesity and tolerance level, as well as related health risks such as cardiovascular disease, apnea and liver disease.

“It is clear that there is a very big market opportunity, but it also requires a portfolio of products that meet different needs of patients,” said Frurgard Jorgensen.